FOR IMMEDIATE RELEASE23 February 2010

                             ReGen Therapeutics Plc

                           Notice of General Meeting

                             Share Issue Authority

The  Board of ReGen Therapeutics Plc  ("ReGen" or "the Company") today announces
that  a General  Meeting of  the Company  will be  held at11.00 a.m. on 11 March
2010 at  the offices of Alexander  David Securities Limited, 10 Finsbury Square,
London, EC2A 1AD.

A  circular  containing  the  Notice  of  General  Meeting  is  being  posted to
shareholders,       and       is       available      on      the      Company's
website:www.regentherapeutics.com 

Introduction

Between  2007 and 2008 losses before tax decreased by over £1,000,000 and whilst
a  further decrease in losses in 2009 is  anticipated, ReGen, is not yet trading
profitably.   The  Directors  have  drastically  reduced costs wherever possible
including  at  least  halving  Directors  salaries  and  further  reducing other
expenses, but additional funds will still be needed to sustain the Company until
such time that it can become profitable.

The  Company has already raised £125,000 in one placing this year with long-term
investors   and   the   Company  has  identified,  from  the  placing  and  from
conversations,  a  number  of  potential  additional long-term investors who are
willing to provide further funding for the Company.

We  set  out  below  the  continuing  roll  out of our worldwide network for the
distribution of Colostrinin(TM).

Current Markets:
USA and Canada
Development   in   the   USA   of  CogniSure(TM)   (Metagenics  brand  name  for
Colostrinin(TM))  has  not  been  as  rapid  as  we had hoped - this remains our
largest  market. We  believe the  takeover of  Metagenics by  Alticor, part of a
worldwide  marketing group with an annual turnover of £3.3 billion, will lead to
our  product  being  more  widely  promoted,  outside  of  the relatively narrow
marketing strategy of the original Metagenics design.  Metagenics advise us that
they  are currently working on positioning the product in the USA and Canada and
expect to carry out a substantial relaunch of the product in 2010.

Australia
The  ban imposed in August 2009 by  the Australian Quarantine Inspection Service
(AQIS)  on the import  of colostrum based  products into Australia  has now been
lifted,  as far  as products  containing Colostrinin(TM)  are concerned.  Health
World in Australia has since ordered material sufficient to make products with a
retail sales value of over US$300,000.

Cyprus
Golgi  Pharmaceuticals Limited has carried  out a significant marketing campaign
to  promote  Cognase(TM)  (Golgi's  brand  name for Colostrinin(TM)) though some
consumers   have  experienced  problems  with  tablets  discolouring.   Upgraded
packaging  has now been developed  by Metagenics to prevent  this problem, and a
supply of this newly packaged product has been delivered to Cyprus.

Poland
Sales  in Poland are proceeding as expected  at the time of signing the original
Test Marketing Agreement in November 2008.

UK
MemoryAid  was successfully launched  in September 2009 and  we are very pleased
that Colostrinin(TM) is finally available in our home market.
Potential markets:
Turkey
Eczacibasi,  a leading  Turkish industrials  group with  annual revenues of $3.2
billion,  now expect the  Government to give  final labelling approval for their
'Dyna(TM)' version of Colostrinin(TM) within the next few weeks and for the full
commercial  launch in Turkey to take place  in the first half of 2010.  We would
remind  Shareholders of the financial terms  of the Turkish agreement which are:
 On  Government approval, Eczacibasi will pay  ReGen a $50,000 milestone payment
and  net  revenues  to  ReGen  from  Eczacibasi,  pursuant to the minimum annual
purchase  commitments in the Distribution Agreement, are estimated to be $52,000
in  the first year, after  regulatory approval is obtained,  and $104,000 in the
second year.

India
ReGen  has a Material Transfer Agreement in  place with an Indian company, which
has  now produced a tablet for the  Indian market.  We are now negotiating final
contract  terms for a  full Licensing and  Distribution Agreement for India.  We
would  comment that  India with  a population  of 1.1 billion  represents a very
significant market where self-medication is a normal feature of medicine.

South Korea
We  are now negotiating the final terms of  a contract with a major South Korean
company  to distribute Colostrinin(TM) in South  Korea.  We believe this company
would have the marketing power to fully exploit the sales potential of a product
based on Colostrinin(TM).

China
Our  contacts through  a technology  transfer company,  sponsoring innovation in
China  from the  UK, has  led to  us signing  a Confidentiality Agreement with a
leading  Chinese pharmaceutical company to  explore the possibility of marketing
Colostrinin(TM) in China.  With a population of 1.3 billion, nearly one fifth of
the  world's population,  China also  represents a  very significant  market for
Colostrinin(TM).  Like India, China also self-medicates and as we are well aware
is an important market for alternative therapies.


The  Board believes that it is in the best interests of Shareholders to continue
to  seek support  for ReGen's  development. The  Company is therefore seeking to
renew  Shareholder  authority  to  take  in  additional  investment  and/or make
acquisitions to maintain the capital base into 2010. The Board wishes to be able
to  be  in  a  position  to  consider  promptly  and  effect appropriate funding
proposals  as  and  when  they  occur  and  is  therefore  now  seeking to renew
Shareholder  authority  to  be  able  to  issue new Ordinary Shares and/or other
securities  of the Company to facilitate future fundraisings and/or acquisitions
of  complementary businesses.   The Board  are requesting  authority to issue up
to20,000,000  new Ordinary Shares for  these specific purposes, which represents
approximately 44.4 per cent. of the current issued share capital of the Company.

In  addition, the Board is seeking renewal of their general authorities to issue
new  Ordinary Shares and/or other securities,  such general authority being last
granted  to them at the General Meeting of the Company held on 7 December 2009.
The  Board are requesting authority to issue up to2,250,000 new Ordinary Shares,
which  represents approximately 5 per cent. of  the current issued share capital
of the Company.

General Meeting

The  grant  of  general  authorities  to  issue  Ordinary  Shares  and/or  other
securities  of the Company requires Shareholder approval. Accordingly, a General
Meeting  of  the  Company  is  being  convened  for  the purpose of granting the
Directors  authority to allot Ordinary Shares and to disapply pre-emption rights
in connection with such allotments.


For further information please contact:

Percy Lomax, ReGen Therapeutics Plc: telephone 020 7153 4920
Roland Cornish/Felicity Geidt, Beaumont Cornish Limited: telephone 020 7628 3396
David   Scott/Nick   Bealer,   Alexander  David  Securities  Limited:  telephone
020 7448 9820



[HUG#1387120]